Current Location:Home > Leadership
  • June Yan MBA
    Co-Founder and CEO

    June is a business executive with over 20 years of experience working in the pharma industry in a variety of markets including the United States, China and Asia.  Prior to founding NeuroFront, June had multiple key leadership roles in pharma MNCs and biotech companies including 17 years in Eli Lilly (China VP, CNS and Bio-Medicines BU head, Asia Marketing Director, HK GM, US CNS district sales manager), Celgene (China GM) and BeiGene (SVP, China Commercial GM). June has brought to NeuroFront in-depth commercial experiences spanning the entire life cycle of some of the top neuroscience brands (Cymbalta, Zyprexa, Prozac, Strattera, and Symbyax), as well as a proven track record in building and growing successful organizations and leading turn-arounds.

    June holds an MBA and an M.S. degree in Biochemistry, both from the University of Maryland (US), and a B.S. degree in Polymer Engineering from Shanghai Jiao Tong University (China).

  • Gary Tong M.D., Ph.D.
    Co-Founder and CMO

    Dr. Tong is a physician scientist and has been involved in patient care, basic and clinical neuroscience research, and drug development over the last 30 years. Before joining NeuroFront, he was the head of clinical science, Takeda Development Center Asia, where he led the physician group in 4 therapeutic areas. Before that, he was with Lundbeck and served as US Therapeutic Area Head in Clinical Research. Before joining Lundbeck, he was Executive Director of Molecule Development group in Covance USA. Prior to Covance, Gary worked for Bristol Myers Squibb USA with increased responsibilities in CNS Discovery Medicine, Clinical Pharmacology and Early Clinical Development.

    Gary obtained his Medical degree and MS in Medicine from The Second Military Medical University, PhD in Neurosciences from Oregon Health Sciences University, and Post-Doctoral Fellow from University of California San Francisco. He is an US board certified neurologist, practiced in University of California San Diego and The Burnham Institute successively as neurology Residency, Clinical Research Fellow and Assistant Professor for over 10 years before he joined pharmaceutical industry. He has authored more than 40 peer-reviewed papers, including articles in Science, Nature, Neurons, and Nature Medicine.

  • Bin Yao M.D., Ph.D.
    Vice President, Commercial and Operations

    Dr. Yao brings over 20 years experiences in the neuroscience area. Before joining NeuroFront, he was the sales and marketing head of neurology at UCB China with a proven track record in the successful commercialization of some of China’s top neurology brands. He was instrumental in bringing Keppra® (Levetiracetam) to exceed $100M annual sales revenue, launching Vimpat® (Lacosamide) and Neupro® (Rotigotine patch) successfully in China. Earlier in his career, Dr. Yao had a variety of sales, marketing, and medical roles in renowned MNCs such as Bayer and Janssen.

    Dr. Yao was a trained neurologist with 9 years clinical practice. He obtained his Ph.D. in Neurology from PLA General Hospital, M.S. in Psychology from Peking University, and Medical degree from the First Military Medical University in China.

  • Simon Tsang PhD

    For nearly 20 years, Simon has had helped organizations create, develop, and partner their most innovative programs or acquire strategic assets. Before joining NeuroFront, Simon has held strategy and business development leadership roles at 28-7, Tesaro, MedImmune/AstraZeneca, Amgen, Constellation, Massachusetts General Hospital, and L.E.K. Consulting. He has helped those companies transform from R&D to commercial stage, build virtual pipelines, make their first forays into emerging markets, and aggressively move into new therapeutic areas of focus. Simons projects have spanned pharmaceuticals, software, and medical devices across many therapeutic areas. His transactional expertise encompasses M&A, global and regional strategic collaborations, co-promotions, platform partnering, and spin-outs. 

    Simon received his Ph.D. in Biophysics from Harvard and B.S. in Molecular Biology from the University of California, San Diego.

  • Kaylen Li
    Vice President, Regulatory Affairs

    Kaylen Li has more than 20 years pharmaceutical product registration, Regulatory Affairs, and team management experience in Industry. Worked for MNCs such as Bayer, Serono, Eli Lilly, Baxter and UCB etc.

    Kaylen obtained B.S in Biology from Lanzhou University, China. Her proven track record was in setting and implementing regulatory strategy in biologics, small molecules, medical devices, and packaging material which covered therapeutic areas of central nervous system, immune, diabetes, oncology, anti-infection etc.

  • Liang Sha M.D.
    Senior Director, Clinical Development
    Dr Sha has over 10 years’experience in drug development for various areas including neuroscience, rare diseases, endocrinology, biosimilars and pediatrics. Before joining NeuroFront, he was the Head of Pharmacovigilance at FibroGen China, where he built the team from scratch and established the full process of pharmacovigilance.  Dr Sha and his team contributed significantly to the approval, launch and post market PV setup of FibroGen’s first-in-class drug Roxadustat in China, 2+ years ahead of United States.  Before FibroGen, he was the associate director at Sanofi Asian Pacific R&D Center where he served as a project lead and clinical lead for various products in development.

    Before joining the pharma industry, Dr Sha was a trained psychiatrist and gynecologist and was in medical practice for 3+ years.  He received his Medical Degree and Master’s Degree in Clinical Psychology from the Medical School of Fudan University in Shanghai, China.
  • Cecily Chen MD, MS
    Senior Director, Clinical Operation

    Dr. Chen has more than 16 years of R&D, medical and marketing experience in the pharmaceutical industry, involving a variety of neurological diseases. Before joining NeuroFront, Ms. Cecily Chen worked in Bayer, AstraZeneca, Merck and other multinational pharmaceutical companies in medical and clinical research positions, accelerating AstraZeneca China's anti-infection and immune disease products to join into the global phase III and phase II clinical trial; Successfully speeded up UCB Keppra to be the first-line treatment in epilepsy.

    Dr. Chen received her medical degree from Shandong First Medical University; and a Master's degree in neuropharmacology from the Academy of Military Medical Sciences.